Utility of Circulating Tumor DNA for Detection and Monitoring of Endometrial Cancer Recurrence and Progression
Despite the increasing incidence of endometrial cancer (EC) worldwide and the poor overall survival of patients who recur, no reliable biomarker exists for detecting and monitoring EC recurrence and progression during routine follow-up. Circulating tumor DNA (ctDNA) is a sensitive method for monitor...
Main Authors: | Esther L. Moss, Diviya N. Gorsia, Anna Collins, Pavandeep Sandhu, Nalini Foreman, Anupama Gore, Joey Wood, Christopher Kent, Lee Silcock, David S. Guttery |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/8/2231 |
Similar Items
-
Systematic characterization of germline variants from the DiscovEHR study endometrial carcinoma population
by: Jason E. Miller, et al.
Published: (2019-05-01) -
HNRNPCL1, PRAMEF1, CFAP74, and DFFB: Common Potential Biomarkers for Sporadic and Suspected Lynch Syndrome Endometrial Cancer
by: Gao Y, et al.
Published: (2020-11-01) -
Cell-Free DNA From Metastatic Pancreatic Neuroendocrine Tumor Patients Contains Tumor-Specific Mutations and Copy Number Variations
by: Gitta Boons, et al.
Published: (2018-11-01) -
Evaluation of Circulating Endometrial Cells as a Biomarker for Endometriosis
by: Ying Chen, et al.
Published: (2017-01-01) -
Circulating Cell-Free DNA or Circulating Tumor DNA in the Management of Ovarian and Endometrial Cancer
by: Chen Q, et al.
Published: (2019-12-01)